Schönborn I, Zschiesche W, Minguillon C, Spitzer E, Möhner M, Ebeling K, Grosse R
Department of Gynecology and Obstetrics, University Hospital Rudolf Virchow Charlottenburg, Freie Universität Berlin, Germany.
J Cancer Res Clin Oncol. 1995;121(2):115-22. doi: 10.1007/BF01202223.
Expression of proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein has been assessed in 471 women with breast cancer to evaluate their prognostic value as compared to conventional histopathological factors. In univariate analysis, high PCNA expression (> or = 20%) predicted a significantly worse survival in lymph-node-negative tumors (univariate P = 0.031). However, the effect disappeared in multivariate analysis and the histological grade remained the only independent factor for this group. Despite its close correlation to histological grade (P < 0.001), PCNA expression discriminated subsets with different survival within the heterogeneous group of moderately differentiated tumors (univariate P = 0.073, multivariate P = 0.075). PCNA expression was not found to be a significant prognostic factor in lymph-node-positive tumors, thus it was of limited value for breast cancer patients as a whole. c-erbB-2 protein overexpression was associated with a worse survival (univariate P = 0.019, multivariate P = 0.057) for the entire group of patients. The effect was mainly attributed to the significance of c-erbB-2 as an independent factor in lymph-node-positive (up to three nodes, multivariate P = 0.04; four or more nodes: multivariate P = 0.017) and large tumors (> 2 cm: multivariate P = 0.002). c-erbB-2 was without significance in lymph-node-negative patients. Though both factors might amplify the prognostic information for distinct patient subsets they do not achieve the strong prognostic value of conventional histopathological features in breast cancer.
对471例乳腺癌女性患者的增殖细胞核抗原(PCNA)和c-erbB-2癌蛋白表达进行了评估,以评价其与传统组织病理学因素相比的预后价值。单因素分析中,PCNA高表达(≥20%)预示淋巴结阴性肿瘤患者的生存率显著更差(单因素P = 0.031)。然而,多因素分析中该效应消失,组织学分级仍是该组唯一的独立因素。尽管PCNA表达与组织学分级密切相关(P < 0.001),但在中度分化肿瘤的异质性组中,PCNA表达可区分不同生存亚组(单因素P = 0.073,多因素P = 0.075)。在淋巴结阳性肿瘤中,未发现PCNA表达是显著的预后因素,因此其对乳腺癌患者总体价值有限。c-erbB-2蛋白过表达与整个患者组的较差生存相关(单因素P = 0.019,多因素P = 0.057)。该效应主要归因于c-erbB-2作为淋巴结阳性(最多3个淋巴结,多因素P = 0.04;4个或更多淋巴结:多因素P = 0.017)和大肿瘤(> 2 cm:多因素P = 0.002)的独立因素的意义。c-erbB-2在淋巴结阴性患者中无意义。尽管这两个因素可能会增强不同患者亚组的预后信息,但它们并未达到乳腺癌传统组织病理学特征的强大预后价值。